Industries > Pharma > Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027

Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027

Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies

PUBLISHED: 21 September 2017
PAGES: 207
PRODUCT CODE: PHA0241

Clear
WOOCS 2.2.1

The Alzheimer’s Disease Therapeutics and Diagnostics Market reached $6.71bn in 2016. The Alzheimer’s Disease Therapeutics and Diagnostics Market is expected to grow at a CAGR of 15.3% in the second half of the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 207-page report you will receive 73 tables and 76 figures– all unavailable elsewhere.

The 207-page report provides clear detailed insight into the Alzheimer’s Disease Therapeutics and Diagnostics Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Alzheimer’s Disease Market forecasts from 2017-2027, further broken down into:
– Alzheimer’s Drugs Market
– Alzheimer’s Diagnostics Market

• Quantitative analysis of the Alzheimer’s drug market from 2017 to 2027. It includes analysis and forecast of top drugs and pipeline drugs in the market:
– Namenda
– Aricept
– Exelon
– Solanezumab
– Gantenerumab
– Verubecestat

• Quantitative analysis of the Alzheimer’s diagnostics market from 2017 to 2027. In includes the guidelines and recent research and development in the field of diagnosis. There is further analysis and forecast provided for subsectors of Alzheimer’s diagnosis from 2017to 2027:
– Diagnostic biomarker market
– Others

• Profiles of leading pharma companies involved in developing Alzheimer’s drugs globally. It contains overviews of the companies’ segments, recent mergers and acquisitions and analysis of the companies’ recent financial performances. It also includes the details of the drugs for Alzheimer’s in the pipeline and forecast of the company drugs available in the market:
– Pfizer
– Eisai
– Actavis
– Lundbeck
– Daiichi Sankyo
– Novartis
– TauRx
– vTv Therapeutics

• Profiles of leading companies developing diagnostics tests for Alzheimer’s disease:
– Eli Lilly
– Amarantus Biosciences Holdings
– Piramal Enterprises
– GE Healthcare
– Navidea
– DiaGenic

Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027• This report also breaks down the revenue forecast for the Alzheimer’s Disease Market by national market:
– US
– Germany
– France
– Italy
– Spain
– UK
– Japan
– China
– Brazil
– India
– Russia

• This report covers the qualitative analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market. It includes SWOT analysis: Strengths, Weaknesses, Opportunities and Threats of the market.

• This report shows transcripts of research interviews conducted by Visiongain:
– David Hung, Chief Executive Officer of Axovant Sciences Inc.
– Dr. Gill Farrar, PET Neurology, Scientific Director at GE Healthcare
– Phyllis Ferrell, Vice President and Alzheimer’s Disease Global Platform Leader at Eli Lilly and Co.

Buy our report today Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027: Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027


Latest Pharma news

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

READ

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

READ

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Categories

Category